Literature DB >> 8035424

Hypoxia-selective antitumor agents. 9. Structure-activity relationships for hypoxia-selective cytotoxicity among analogues of 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide.

B D Palmer1, W R Wilson, G J Atwell, D Schultz, X Z Xu, W A Denny.   

Abstract

A series of analogues of the novel hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide (6) have been prepared and evaluated, in a search for compounds which retain high hypoxic selectivity but have increased potency and/or aqueous solubility. Several analogues with ionizable or dipolar carboxamide side chains showed improved solubility but generally had reduced cytotoxic potency and hypoxic selectivity. Modification of the mustard leaving groups or replacement of the carboxamide moiety provided some compounds with superior potency, but only the mixed chloro/mesylate mustard 20 provided a gain in potency relative to solubility while retaining the hypoxic selectivity of 6. These nitrogen mustards did not show the remarkable activity demonstrated by the related aziridine 7 [CB 1954, 5-(N-aziridinyl)- 2,4-dinitrobenzamide] in Walker 256 adenocarcinoma cells and are not efficient substrates for the DT-diaphorase which activates the latter compound by aerobic nitroreduction in Walker cells. Variations in hypoxic selectivity within the dinitrobenzamide mustards appear not to be due to differences in sensitivity to activation by this enzyme. Walker cells showed intermediate sensitivity to the mono(2-chloroethyl) analogue 26 but not to the related half-mustard 27, suggesting that the inhibition of DT-diaphorase activity is due to steric effects in the 5-position. The preferred compound overall with respect to solubility, potency, and in vitro hypoxic cell selectivity was the (dimethylamino)-ethyl derivative 11. DNA elution studies and comparison of the sensitivity of AA8 and UV4 cells to this compound indicated reductive activation to form a DNA cross-linking agent under hypoxia. Radiobiological studies indicated 11 to be equally active against both aerobic and hypoxic cells in KHT tumors. It is not clear whether this reflects efficient killing of aerobic cells as a result of diffusion of reduced metabolites from hypoxic regions or whether cytotoxicity in tumors is independent of hypoxia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8035424     DOI: 10.1021/jm00040a009

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  Bioreductive prodrug PR-104 improves the tumour distribution and titre of the nitroreductase-armed oncolytic adenovirus ONYX-411NTR leading to therapeutic benefit.

Authors:  Dean C Singleton; Alexandra M Mowday; Chris P Guise; Sophie P Syddall; Sally Y Bai; Dan Li; Amir Ashoorzadeh; Jeff B Smaill; William R Wilson; Adam V Patterson
Journal:  Cancer Gene Ther       Date:  2021-11-26       Impact factor: 5.854

2.  Prodrugs for Gene-Directed Enzyme-Prodrug Therapy (Suicide Gene Therapy).

Authors:  William A. Denny
Journal:  J Biomed Biotechnol       Date:  2003

Review 3.  Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy.

Authors:  Zhe Fu; Alexandra M Mowday; Jeff B Smaill; Ian F Hermans; Adam V Patterson
Journal:  Cells       Date:  2021-04-24       Impact factor: 6.600

4.  Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs.

Authors:  C J Lash; A E Li; M Rutland; B C Baguley; L J Zwi; W R Wilson
Journal:  Br J Cancer       Date:  1998-08       Impact factor: 7.640

Review 5.  Bystander or no bystander for gene directed enzyme prodrug therapy.

Authors:  Gabi U Dachs; Michelle A Hunt; Sophie Syddall; Dean C Singleton; Adam V Patterson
Journal:  Molecules       Date:  2009-11-10       Impact factor: 4.411

6.  Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3.

Authors:  Maria R Abbattista; Amir Ashoorzadeh; Christopher P Guise; Alexandra M Mowday; Rituparna Mittra; Shevan Silva; Kevin O Hicks; Matthew R Bull; Victoria Jackson-Patel; Xiaojing Lin; Gareth A Prosser; Neil K Lambie; Gabi U Dachs; David F Ackerley; Jeff B Smaill; Adam V Patterson
Journal:  Pharmaceuticals (Basel)       Date:  2021-11-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.